2023年3月31日

临床研究成本大制药公司每年大约15%的销售,有一个实验花费多达500美元,经常涉及成千上万的病人之前可以通过市场的一种新方法。添加,事实上,70%的临床研究发生在相同的设施,5%,只有5%的病人进行临床试验。缺乏耐心的访问会导致审判延迟,推高了成本和令人窒息的医疗创新和病人的多样性。巴黎Inato改善,一个平台,使更多的人接受临床试验,提出了20美元在一系列A2轮融资。筹资包括返回,导致投资者国泰创新、回报投资者明显的企业,资本和新投资者La Maison和收成。新的资金将支持公司的持续的产品创新,国际扩张,顶尖人才的招聘。扩大产品提供法国公司还将扩大其多样性产品帮助赞助商实现多元化目标的新的FDA法规。为了改善护理,该公司还将投资于oncology-specific创新。“Inato我们扭转这一趋势翻转模型和授权research-experienced社区网站访问正确的试验他们的团队和当地居民——不管他们是谁或他们住的地方,“说Inato联合创始人兼首席执行官Kourosh Davarpanah。“这还使赞助商与更广泛的社区研究验证合作网站,减少竞争,加速网站激活,并增加病人的访问。” “Our repeat investment in Inato represents our strong conviction in the company’s mission, team, and continued success as an emerging leader and pioneer when it comes to changing the status quo in clinical trial diversity and access,” said Jean-François Cochy, partner at Cathay Innovation. “At Cathay, we strongly believe in supporting the emergence of global leaders in digital health, and Inato is a bright example through its adoption by hospitals in 60 countries and pharmaceutical groups from all regions. Inato also reflects the strength of the Cathay ecosystem with its strong collaboration with our strategic partner Sanofi.” “At Obvious, we support entrepreneurs solving humanity’s biggest challenges — and Inato is doing just that,” said Rohan Ganesh, partner at Obvious Ventures. “Inato is playing a critical role in enabling clinical research to keep pace with patient diversity and inclusion, along with being really technologically innovative.” Inato, which was founded in 2020, makes clinical trials more accessible, inclusive, and efficient for patients, community-based clinical researchers, and pharmaceutical corporations worldwide. The platform connects multinational pharmaceutical corporations with a larger network of community research sites, making it easier to match the correct trial to the right patient. Since its debut, the startup has swiftly established itself as a trusted two-sided platform, with over 2,500 community research sites supporting more than 70 disease categories in more than 60 countries. To date, the company has forged alliances with one-third of the top 30 pharmaceutical companies in order to make medical research more accessible, inclusive, and efficient. Cathay Innovation is a global venture funding business founded by Cathay Capital. It makes startup investments in North America, Latin America, Europe, Asia, and Africa. A multi-stage fund with over $2B in assets under management, it collaborates with visionary entrepreneurs and firms that are positively influencing the world through technology.